IMPROVE 2022 International Meeting on Pathway-Related Obesity: Vision of Excellence.

Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101560587 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1758-8111 (Electronic) Linking ISSN: 17588103 NLM ISO Abbreviation: Clin Obes Subsets: MEDLINE

Original Publication: Oxford : Wiley-Blackwell

Obesity*/therapy ; Receptor, Melanocortin, Type 4*/genetics ; Receptor, Melanocortin, Type 4*/metabolism; Humans ; Hyperphagia ; Signal Transduction

Nearly 90 clinicians and researchers from around the world attended the first IMPROVE 2022 International Meeting on Pathway-Related Obesity. Delegates attended in person or online from across Europe, Argentina and Israel to hear the latest scientific and clinical developments in hyperphagia and severe, early-onset obesity, and set out a vision of excellence for the future for improving the diagnosis, treatment, and care of patients with melanocortin-4 receptor (MC4R) pathway-related obesity. The meeting co-chair Peter Kühnen, Charité Universitätsmedizin Berlin, Germany, indicated that change was needed with the rapidly increasing prevalence of obesity and the associated complications to improve the understanding of the underlying mechanisms and acknowledge that monogenic forms of obesity can play an important role, providing insights that can be applied to a wider group of patients with obesity. World-leading experts presented the latest research and led discussions on the underlying science of obesity, diagnosis (including clinical and genetic approaches such as the role of defective MC4R signalling), and emerging clinical data and research with targeted pharmacological approaches. The aim of the meeting was to agree on the questions that needed to be addressed in future research and to ensure that optimised diagnostic work-up was used with new genetic testing tools becoming available. This should aid the planning of new evidence-based treatment strategies for the future, as explained by co-chair Martin Wabitsch, Ulm University Medical Center, Germany.
(© 2024 The Authors. Clinical Obesity published by John Wiley & Sons Ltd on behalf of World Obesity Federation.)

Schwimmer JB, Burwinkle TM, Varni JW. Health‐related quality of life of severely obese children and adolescents. JAMA. 2003;289(14):1813‐1819.
Krude H, Biebermann H, Luck W, Horn R, Brabant G, Grüters A. Severe early‐onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. 1998;19(2):155‐157.
Loos RF. Genetic determinants of common obesity and their value in prediction. Best Pract Res Clin Endocrinol Metab. 2012;26(2):211‐226.
Hatoum IJ, Stylopoulos N, Vanhooose AM, et al. Melanocortin‐4 receptor signaling is required for weight loss after gastric bypass surgery. J Clin Endocrinol Metab. 2012;97(6):E1023‐E1031.
Poitou C, Puder L, Dubern B, et al. Long‐term outcomes of bariatric surgery in patients with bi‐allelic mutations in the POMC, LEPR, and MC4R genes. Surg Obes Relat Dis. 2021;17(8):1449‐1456.
Kühnen P, Clément K. Long‐term MC4R agonist treatment in POMC‐deficient patients. N Engl J Med. 2022;387(9):852‐854.
Jackson RS, Creemers JW, Ohagi S, et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet. 1997;16(3):303‐306.
Marenne G, Hendricks AE, Perdikari A, et al. Exome sequencing identifies genes and gene sets contributing to severe childhood obesity, linking PHIP variants to repressed POMC transcription. Cell Metab. 2020;31(6):1107‐1119.
Collet TH, Dubern B, Mokrosinski J, et al. Evaluation of a melanocortin‐4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency. Mol Metab. 2017;6(10):1321‐1329.
Farooqi IS, Keogh JM, Yeo GS, Lank EJ, Cheetham T, O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med. 2003;348(12):1085‐1095.
Styne DM, Arslanian SA, Connor EL, et al. Pediatric obesity‐assessment, treatment, and prevention: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017;102(3):709‐757.
Kühnen P, Clément K, Wiegand S, et al. Proopiomelanocortin deficiency treated with a melanocortin‐4 receptor agonist. N Engl J Med. 2016;375(3):240‐246.
Clément K, Biebermann H, Farooqi S, et al. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency. Nat Med. 2018;24(5):551‐555.
Clément K, van den Akker E, Argente J, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single‐arm, open‐label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960‐970.
Steuernagel L, Lam BYH, Klemm P, et al. HypoMap—a unified single‐cell gene expression atlas of the murine hypothalamus. Nat Metab. 2022;4:1402‐1419.
Katsanis N, Lupski JR, Beales PL. Exploring the molecular basis of Bardet‐Biedl syndrome. Hum Mol Genet. 2001;10(20):2293‐2299.
Forsythe E, Beales PL. Bardet‐Biedl syndrome. Eur J Hum Genet. 2013;21(1):8‐13.
Beales PL, Elcioglu N, Woolf AS, Parker D, Flinter FA. New criteria for improved diagnosis of Bardet‐Biedl syndrome: results of a population survey. J Med Genet. 1999;36(6):437‐446.
Chandra B, Tung ML, Hsu Y, Scheetz T, Sheffield VC. Retinal ciliopathies through the lens of Bardet‐Biedl Syndrome: past, present and future. Prog Retin Eye Res. 2021;89:101035.
Mitchison HM, Valente EM. Erratum in: Motile and non‐motile cilia in human pathology: from function to phenotypes. J Pathol. 2017;241(2):294–309. J Pathol. 2017;241(4):564.
Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(3):1‐203.
Di Cesare M, Sorić M, Bovet P, et al. The epidemiological burden of obesity in childhood: a worldwide epidemic requiring urgent action. BMC Med. 2019;17(1):212.
Clément K, Mosbah H, Poitou C. Rare genetic forms of obesity: from gene to therapy. Physiol Behav. 2020;227:113134.
Kleinendorst L, Abawi O, van der Voorn B, et al. Identifying underlying medical causes of pediatric obesity: results of a systematic diagnostic approach in a pediatric obesity center. PLoS One. 2020;15(5):e0232990.
Dent R, McPherson R, Harper ME. Factors affecting weight loss variability in obesity. Metabolism. 2020;113:154388.
Kusminski CM, Bickel PE, Scherere PE. Targeting adipose tissue in the treatment of obesity‐associated diabetes. Nat Rev Discov. 2016;15(9):639‐660.
Anderson EK, Gutierrez DA, Kennedy A, Hasty AH. Weight cycling increases T‐cell accumulation in adipose tissue and impairs systemic glucose tolerance. Diabetes. 2013;62(9):3180‐3188.
Zou J, Lai B, Zheng M, et al. CD4+ T cells memorize obesity and promote weight regain. Cell Mol Immunol. 2018;15(6):630‐639.
Henegar C, Tordjman J, Achard V, et al. Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. Genome Biol. 2008;9(1):R14.
Abdennour M, Reggio S, Le Naour G, et al. Association of adipose tissue and liver fibrosis with tissue stiffness in morbid obesity: links with diabetes and BMI loss after gastric bypass. J Clin Endocrinol Metab. 2014;99(3):898‐907.
Lacroix D, Moutel S, Coupaye M, et al. Metabolic and adipose tissue signatures in adults with Prader‐Willi syndrome: a model of extreme adiposity. J Clin Endocrinol Metab. 2015;100(3):850‐859.
Cotillard A, Kennedy SP, Kong LC, et al. Dietary intervention impact on gut microbial gene richness. Nature. 2013;500(7464):585‐588.
Dao MC, Everard A, Aron‐Wisnewsky J, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2016;65(3):426‐436.
Aron‐Wisnewsky J, Prifti E, Belda E, et al. Major microbiota dysbiosis in severe obesity: fate after bariatric surgery. Gut. 2019;68(1):70‐82.
Vieira‐Silva S, Falony G, Belda E, et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature. 2020;581(7808):310‐315.
Fromentin S, Forslund SK, Chechi K, et al. Microbiome and metabolome features of the cardiometabolic disease spectrum. Nat Med. 2022;28(2):303‐314.
Olsson LM, Poitou C, Tremarolli V, et al. Gut microbiota of obese subjects with Prader‐Willi syndrome is linked to metabolic health. Gut. 2020;69(7):1229‐1238.
Juvonen J, Lessard LM, Schacter HL, Suchilt L. Emotional implications of weight stigma across middle school: the role of weight‐based peer discrimination. J Clin Child Adolesc Psychol. 2017;46(1):150‐158.
Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. Nat Med. 2020;26(4):485‐497.
Schvey NA, Marwitz SE, Mi SJ, et al. Weight‐based teasing is associated with gain in BMI and fat mass among children and adolescents at‐risk for obesity: a longitudinal study. Pediatr Obes. 2019;14(10):e12538.
Haqq AM, Kebbe M, Tan Q, Manco M, Salas XR. Complexity and stigma of pediatric obesity. Child Obes. 2021;17(4):229‐240.
Hagan S. E66.01 and our culture of shame. N Engl J Med. 2021;385(25):2307‐2309.
Li X, Cope MB, Johnson MS, Smith DL Jr, Nagy TR. Mild calorie restriction induces fat accumulation in female C57BL/6J mice. Obesity (Silver Spring). 2010;18(3):456‐462.
Kashani A, Brejnrod AD, Jin C, et al. Impaired glucose metabolism and altered gut microbiome despite calorie restriction of ob/ob mice. Anim Microbiome. 2019;1(1):11.
Holm JC, Gamborg M, Bille DS, Gr Nb K HN, Ward LC, Faerk J. Chronic care treatment of obese children and adolescents. Int J Pediatr Obes. 2011;6(3–4):188‐196.
Fogh M, Lund MAV, Mollerup PM, et al. Disturbed eating behaviours do not impact treatment response in a paediatric obesity chronic care treatment programme. J Paediatr Child Health. 2020;56(4):542‐549.
Iepsen EW, Zhang J, Thomsen HS, et al. Patients with obesity caused by melanocortin‐4 receptor mutations can be treated with a glucagon‐like peptide‐1 receptor agonist. Cell Metab. 2018;28(1):23‐32.e3.
Ahima RS, Flier JS. Leptin. Annu Rev Physiol. 2000;62:413‐437.
Mattar L, Huas C, Duclos J, Apfel A, Godart N. Relationship between malnutrition and depression or anxiety in anorexia nervosa: a critical review of the literature. J Affect Disord. 2011;132(3):311‐318.
Sadoul BC, Schuring EAH, Mela DJ, Peters HPF. The relationship between appetite scores and subsequent energy intake: an analysis based on 23 randomized controlled studies. Appetite. 2014;83:153‐159.
Hopkins M, Beaulieu K, Myers A, Gibbons C, Blundell JE. Mechanisms responsible for homeostatic appetite control: theoretical advances and practical implications. Expert Rev Endocrinol Metab. 2017;12(6):401‐415.
Casanova N, Bosy‐Westphal A, Beaulieu K, et al. Associations between high‐metabolic rate organ masses and fasting hunger: a study using whole‐body magnetic resonance imaging in healthy males. Physiol Behav. 2022;250:113796.
Editors. Definitions in epigenetics. Ann N Y Acad Sci. 2003;983(1):321‐328.
Lechner L, Opitz R, Silver MJ, et al. Early‐set POMC methylation variability is accompanied by increased risk for obesity and is addressable by MC4R agonist treatment. Sci Transl Med. 2023;15(705):eadg1659.
Rayco‐Solon P, Moore SE, Fulford AJ, Prentice AM. Fifty‐year mortality trends in three rural African villages. Trop Med Int Health. 2004;9(11):1151‐1160.
Moore SE, Cole TJ, Pokitt EM, et al. Season of birth predicts mortality in rural Gambia. Nature. 1997;388(6641):434.
Waterland RA, Kellermayer R, Laritsky E, et al. Season of conception in rural Gambia affects DNA methylation at putative human metastable epialleles. PLoS Genet. 2010;6(12):e1001252.
Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. J Clin Invest. 2011;121(6):2094‐2101.
Arner P, Bernard S, Salehpour M, et al. Dynamics of human adipose lipid turnover in health and metabolic disease. Nature. 2011;478(7367):110‐113.
Rydén M, Andersson DP, Bernard S, Spalding K, Arner P. Adipocyte triglyceride turnover and lipolysis in lean and overweight subjects. J Lipid Res. 2013;54(10):2909‐2913.
Spalding KL, Bernard S, Näslund E, et al. Impact of fat mass and distribution on lipid turnover in human adipose tissue. Nat Commun. 2017;8:15253.
Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. Diabetologia. 2000;43(12):1498‐1506.
Lönn M, Mehlig K, Bengtsson C, Lissner L. Adipocyte size predicts incidence of type 2 diabetes in women. FASEB J. 2010;24(1):326‐331.
Arner E, Westermark PO, Spalding KL, et al. Adipocyte turnover: relevance to human adipose tissue morphology. Diabetes. 2010;59(1):105‐109.
Hoffstedt J, Arner E, Wahrenberg H, et al. Regional impact of adipose tissue morphology on the metabolic profile in morbid obesity. Diabetologia. 2010;53(12):2496‐2503.
Bäckdahl J, Franzén L, Massier L, et al. Spatial mapping reveals human adipocyte subpopulations with distinct sensitivities to insulin. Cell Metab. 2021;33(9):1869‐1882.e6.
Sumithran P, Prendergast LA, Delbridge E, et al. Long‐term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597‐1604.
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425‐432.
Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG, O'Rahilly S. A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet. 1998;20(2):111‐112.
Tschöp M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000;407(6806):908‐913.
Tschöp M, Wawarta R, Riepl RL, et al. Post‐prandial decrease of circulating human ghrelin levels. J Endocrinol Invest. 2001;24(6):RC19‐RC21.
Clemmensen C, Müller TD, Wood SC, Berthoud H‐R, Seeley RJ, Tschöp MH. Gut‐brain cross‐talk in metabolic control. Cell. 2017;168(5):758‐774.
Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschöp MH. The metabolic actions of glucagon revisited. Nat Rev Endocrinol. 2010;6(10):689‐697.
Müller TD, Finan B, Clemmensen C, DiMarchi RD, Tschöp MH. The new biology and pharmacology of glucagon. Physiol Rev. 2017;97(2):721‐766.
Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP‐1 co‐agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5(10):749‐757.
Nahra R, Wang T, Gadde KM, et al. Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54‐week randomized phase 2b study. Diabetes Care. 2021;44(6):1433‐1442.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205‐216.
Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP‐1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double‐blind, placebo‐controlled, randomised, multiple‐ascending dose trial. Lancet. 2022;400(10366):1869‐1881.
von Schnurbein J, Remy M, Brandt S, et al. Positive effect of leptin substitution on mood and behaviour in patients with congenital leptin deficiency. Pediatr Obes. 2023;18(8):e13057.

Rhythm Pharmaceuticals

Keywords: MC4R pathway; early‐onset obesity; genetic obesity; hyperphagia; severe obesity

0 (MC4R protein, human)
0 (Receptor, Melanocortin, Type 4)

Date Created: 20240411 Date Completed: 20240513 Latest Revision: 20240717

20240717

10.1111/cob.12659

38602039